Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Revolution (RVMD) PT Raised to $55 at JPMorgan
July 16, 2024 5:52 AM EDTJPMorgan analyst Eric Joseph raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $42.00) while maintaining a Overweight rating.
The analyst comments "Revisiting our model on the heels of updated phase 1 results for RMC-6236 in 2L+ PDAC, were establishing a Dec-25 price target of $55 (vs prior Dec-24 PT of $42). Key changes to our model include accelerated launch timing (2028 vs 2029 prior) based upon guided... More
Revolution (RVMD) PT Raised to $55 at BofA Securities
July 16, 2024 5:47 AM EDTBofA Securities analyst Alec Stranahan raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "RVMD shares were up (+5.5%, NBI: flat) on the back of what we would characterize as a best-case readout for RMC-6236... More
Revolution (RVMD) PT Raised to $73 at Jefferies
July 15, 2024 4:03 PM EDTJefferies analyst Kelly Shi raised the price target on Revolution (NASDAQ: RVMD) to $73.00 (from $63.00) while maintaining a Buy rating.
The analyst comments "With the new PDAC data, we think the odds are tipping even higher now for RVMD's multi-selective RASi to... More
Revolution (RVMD) PT Raised to $57 at Stifel
July 15, 2024 1:42 PM EDTStifel analyst Ben Burnett raised the price target on Revolution (NASDAQ: RVMD) to $57.00 (from $43.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating and increasing our TP to $57/share following RMC-6236 (RAS-multi) monotherapy results in PDAC which... More
